Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, which may reverse lymphoid exhaustion and alter the cell trafficking of inflammatory cells, has been tested in clinical trials for severe COVID-19 (ClinicalTrials.gov Identifier: NCT04435522, NCT04441385, and NCT04475991). Here, CCR5 is linked to COVID-19.